Flavivirus VLP
Flavivirus virus-like particles (VLPs) are non-infectious nanoparticles that mimic the structural and antigenic properties of flaviviruses without containing their genetic material. Members of the Flavivirus genus include medically important pathogens such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV).
Structure of Flavivirus VLPs
Flavivirus VLPs are composed of structural proteins that self-assemble into particles resembling the native virion:
- Envelope Protein (E): Mediates attachment and entry into host cells; the primary target for neutralizing antibodies.
- Pre-membrane/Membrane Protein (prM/M): Plays a critical role in VLP assembly and maturation.
- Capsid Protein (C): Typically omitted in VLPs as it packages viral RNA in native viruses, which is absent in VLPs.
Production Systems
Flavivirus VLPs are produced in various expression systems tailored to the desired application:
- Mammalian Cells: Preferred for producing glycoproteins (E and prM) with accurate post-translational modifications, including glycosylation.
- Insect Cells: Widely used due to the high yield and scalability of the baculovirus expression system.
- Plant-Based Systems: Emerging as a scalable and economical platform for VLP production.
Applications
- Vaccines
- Prophylactic Vaccines: Flavivirus VLP-based vaccines elicit strong neutralizing antibody responses, particularly targeting the envelope (E) protein, providing protection against specific flaviviruses (e.g., DENV, ZIKV, WNV, JEV).
- Diagnostics
- Flavivirus VLPs serve as antigens in serological assays for detecting virus-specific antibodies, distinguishing infections by flaviviruses with overlapping symptoms.
- Immunological Research
- Used to study flavivirus-host interactions, immune responses, and mechanisms of antibody-dependent enhancement (ADE), which complicates vaccine development for certain flaviviruses like DENV.
Flavivirus virus-like particles represent a promising approach for developing safe and effective vaccines, diagnostics, and therapeutic tools to combat flavivirus infections. Their adaptability and ability to mimic native virus structures make them invaluable in addressing the global burden of flavivirus-related diseases. Advances in VLP technology aim to optimize their production, efficacy, and accessibility, enhancing their potential for widespread application.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|